Clinical trial

A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6…

NCT00001116 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed

Key facts

NCT number NCT00001116
Title A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-alpha (Tumor Necrosis Factor) in HIV-Infected Patients
Official title Effect of Recombinant Human Soluble Tumor Necrosis Factor Receptor (TNFR:Fc) on Interleukin-6 (IL-6), Tumor Necrosis Factor-Alpha (TNF-alpha) and Markers of Immune Activation in HIV-Infected Subjects
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID), NIH
Status Completed
Study type Interventional
Conditions HIV Infections
Intervention type Drug
Interventions Tumor Necrosis Factor soluble receptor-immunoadhesin complex
Enrollment 18
Completion Jun 1, 2000
First posted Aug 31, 2001
Last update posted Nov 1, 2021
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies